Merck’s EMD Serono to expand biopharma R&D facility with $70m investment
February 16, 2019 No Comment
German pharma company Merck will invest $70 million for the expansion of its US and Canada biopharma business EMD Serono’s research and development (R&D) facility in Billerica, Massachusetts. The expansion of the R&D facility through the addition of a new building is expected to enable drug discoveries in the areas of oncology, immuno-oncology and immunology. […]
Continue reading …
Merck has bagged the European Commission approval for the combination of its anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) with Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum chemotherapy for the treatment of a certain form of metastatic nonsquamous non-small cell lung cancer (NSCLC). The latest Keytruda approval is for the use of the cancer combination therapy as […]
Continue reading …
Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab) in advanced solid tumors. According to Alkermes, ALKS 4230 is an engineered fusion protein which selectively binds and signals […]
Continue reading …
Lenvima FDA appoval : Eisai and Merck announced that the US Food and Drug Administration (FDA) has approved their kinase inhibitor Lenvima (lenvatinib) capsules for first-line treatment of hepatocellular carcinoma (HCC), a common type of primary liver cancer adults. Lenvima FDA approval, which is for HCC that is unresectable, was driven by results of the […]
Continue reading …Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab
July 18, 2018 No Comment
Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination of Voyager-V1 and Bavencio (avelumab), respectively, for metastatic colorectal cancer. According to Vyriad, Voyager-V1 is an oncolytic virotherapy which is a bullet-shaped, negative-sense RNA virus having low human seroprevalence. The […]
Continue reading …
Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease. The Keytruda chemotherapy combination has been approved to treat metastatic non-squamous non small cell lung […]
Continue reading …
Business News Today
- TASI acquires German inspection systems manufacturer Cassel Messtechnik
- ALX Oncology raises $105m to advance clinical development of ALX148
- ImmunogenX enrolls patients for Solutions for Celiac trial of Latiglutenase
- McDermott wins contract for six crude oil storage tanks in Texas
- Badin IV South Block, Pakistan : Petroleum Exploration, Jura Energy begin commercial production
- Google wraps up $2.6bn acquisition of data platform company Looker
- ABG buys majority stake in spirits distribution company Indie Brands
- Arthur J. Gallagher acquires Illinois-based Affiliated Benefit Consultants
- Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer
- Antios Therapeutics begins phase 1 trial for ATI-2173, a chronic hepatitis B candidate
